The aim of this study is to systemically analyze the association of CYP1A1 gene MspI and Ile462Val polymorphisms with cervical cancer susceptibility.

Material and methods:
The publications about the associations between CYP1A1 polymorphism and cervical cancer were retrieved through PubMed, Embase, Chinese Biomedical Literature Database, Wanfang Data, Database of Chinese Scientific and Technical Periodicals (VIP) and China Knowledge Network. The Hardy-Weinberg equilibrium test was used to evaluate the quality of the included studies, and the data in the studies selected were analyzed by Stata 12.0 software. Potential publication bias was assessed with funnel plots and a modified Egger’s linear regression test.

A total of 17 studies were enrolled in this analysis. There were 14 articles on the MspI polymorphism, including 2448 cases and 2520 controls. We found a significant association between MspI polymorphism and cervical cancer susceptibility (C vs. T, OR = 1.333, 95% CI: 1.214–1.464, p ≤ 0.001; CC vs. TT, OR = 1.962, 95% CI: 1.571–2.450, p ≤ 0.001; CC/CT vs.TT, OR = 1.591, 95% CI: 1.406–1.800, p ≤ 0.001; CC vs.TT/CT, OR = 1.429, 95% CI: 1.177–1.736, p ≤ 0.001). In total, 11 articles, including 2137 cases and 2116 controls, analyzed the Ile462Val polymorphism and the risk of cervical cancer. The results showed a significant association between Ile462Val polymorphism and cervical cancer susceptibility (Val vs. Ile, OR = 1.338, 95% CI: 1.199–1.493, p ≤ 0.001; ValVal vs. IleIle, OR = 1.576, 95% CI: 1.188–2.090, p = 0.002; ValVal/ValIle vs. IleIle, OR = 1.498; 95% CI: 1.299–1.728, p ≤ 0.001).

Both MspI and Ile462Val polymorphisms of the CYP1A1 gene are associated with the risk of cervical cancer.

Journals System - logo
Scroll to top